Literature DB >> 23959311

Oral DAV131, a charcoal-based adsorbent, inhibits intestinal colonization by β-lactam-resistant Klebsiella pneumoniae in cefotaxime-treated mice.

Nathalie Grall1, Laurent Massias, Thu Thuy Nguyen, Sakina Sayah-Jeanne, Nicolas Ducrot, Elisabeth Chachaty, Jean de Gunzburg, Antoine Andremont.   

Abstract

Antibiotics excreted into the intestinal tract, such as broad-spectrum cephalosporins, disrupt the indigenous microflora, affect colonization resistance (CR), and promote intestinal colonization by resistant bacteria. We tested whether oral DAV131, a charcoal-based adsorbent, would prevent colonization by a cefotaxime (CTX)-resistant Klebsiella pneumoniae strain (PUG-2) in CTX-treated mice. Mice received CTX, saline, CTX and DAV131, or saline and DAV131 for 3 days before oral challenge with 10(6) CFU of PUG-2. The fecal CTX concentrations and counts of PUG-2 were assayed. Fecal CTX disappeared when DAV131 was given concomitantly with CTX (P < 0.05), and the area under the curve of PUG-2 fecal density was significantly reduced (P < 0.01). In conclusion, reducing intestinal antibiotic exposure with DAV131 may reduce colonization by resistant strains during treatment compared to treatment with CTX only. This might open new possibilities for decreasing the impact of antibiotics on the intestinal microbiota during treatments.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23959311      PMCID: PMC3811274          DOI: 10.1128/AAC.00039-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Inactivation of ceftriaxone by faecal enzyme preparations during ceftriaxone treatment.

Authors:  G W Welling; A Holtrop; C Slootmaker-van der Meulen; G J Meijer-Severs; E van Santen; R H Tonk; H G de Vries-Hospers; D van der Waaij
Journal:  J Antimicrob Chemother       Date:  1992-08       Impact factor: 5.790

Review 2.  The role of the intestinal tract as a reservoir and source for transmission of nosocomial pathogens.

Authors:  Curtis J Donskey
Journal:  Clin Infect Dis       Date:  2004-06-25       Impact factor: 9.079

Review 3.  Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens.

Authors:  Alain L Servin
Journal:  FEMS Microbiol Rev       Date:  2004-10       Impact factor: 16.408

Review 4.  The gut flora as a forgotten organ.

Authors:  Ann M O'Hara; Fergus Shanahan
Journal:  EMBO Rep       Date:  2006-07       Impact factor: 8.807

Review 5.  Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America.

Authors:  Helen W Boucher; George H Talbot; John S Bradley; John E Edwards; David Gilbert; Louis B Rice; Michael Scheld; Brad Spellberg; John Bartlett
Journal:  Clin Infect Dis       Date:  2009-01-01       Impact factor: 9.079

6.  STREPTOMYCIN treatment of pulmonary tuberculosis.

Authors: 
Journal:  Br Med J       Date:  1948-10-30

Review 7.  Colonization resistance.

Authors:  E J Vollaard; H A Clasener
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

8.  Outpatient antibiotic use in Europe and association with resistance: a cross-national database study.

Authors:  Herman Goossens; Matus Ferech; Robert Vander Stichele; Monique Elseviers
Journal:  Lancet       Date:  2005 Feb 12-18       Impact factor: 79.321

9.  Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes.

Authors:  E Lautenbach; J B Patel; W B Bilker; P H Edelstein; N O Fishman
Journal:  Clin Infect Dis       Date:  2001-03-26       Impact factor: 9.079

Review 10.  IPSAT P1A, a class A beta-lactamase therapy for the prevention of penicillin-induced disruption to the intestinal microflora.

Authors:  Johann D D Pitout
Journal:  Curr Opin Investig Drugs       Date:  2009-08
View more
  9 in total

1.  Protection of Hamsters from Mortality by Reducing Fecal Moxifloxacin Concentration with DAV131A in a Model of Moxifloxacin-Induced Clostridium difficile Colitis.

Authors:  Charles Burdet; Sakina Sayah-Jeanne; Thu Thuy Nguyen; Christine Miossec; Nathalie Saint-Lu; Mark Pulse; William Weiss; Antoine Andremont; France Mentré; Jean de Gunzburg
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

2.  Antibiotic-Induced Dysbiosis Predicts Mortality in an Animal Model of Clostridium difficile Infection.

Authors:  France Mentré; Jean de Gunzburg; Charles Burdet; Sakina Sayah-Jeanne; Thu Thuy Nguyen; Perrine Hugon; Frédérique Sablier-Gallis; Nathalie Saint-Lu; Tanguy Corbel; Stéphanie Ferreira; Mark Pulse; William Weiss; Antoine Andremont
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

Review 3.  Antimicrobial resistance in the next 30 years, humankind, bugs and drugs: a visionary approach.

Authors:  Matteo Bassetti; Garyphallia Poulakou; Etienne Ruppe; Emilio Bouza; Sebastian J Van Hal; Adrian Brink
Journal:  Intensive Care Med       Date:  2017-07-21       Impact factor: 17.440

4.  A murine model to study the gut bacteria parameters during complex antibiotics like cefotaxime and ceftriaxone treatment.

Authors:  Matthieu Grégoire; Florian Berteau; Ronan Bellouard; Quentin Lebastard; Philippe Aubert; Jacques Gonzales; François Javaudin; Anne Bessard; Pascale Bemer; Éric Batard; Didier Lepelletier; Michel Neunlist; Emmanuel Montassier; Éric Dailly
Journal:  Comput Struct Biotechnol J       Date:  2021-03-04       Impact factor: 7.271

5.  The production of Necator americanus larvae for use in experimental human infection.

Authors:  Paul R Chapman; Stacey Llewellyn; Helen Jennings; Luke Becker; Paul Giacomin; Rodney McDougall; Jennifer Robson; Alex Loukas; James McCarthy
Journal:  Parasit Vectors       Date:  2022-07-08       Impact factor: 4.047

6.  Public health evolutionary biology of antimicrobial resistance: priorities for intervention.

Authors:  Fernando Baquero; Val F Lanza; Rafael Cantón; Teresa M Coque
Journal:  Evol Appl       Date:  2014-12-11       Impact factor: 5.183

7.  An open randomized multicentre Phase 2 trial to assess the safety of DAV132 and its efficacy to protect gut microbiota diversity in hospitalized patients treated with fluoroquinolones.

Authors:  Maria J G T Vehreschild; Annie Ducher; Thomas Louie; Oliver A Cornely; Celine Feger; Aaron Dane; Marina Varastet; Fabien Vitry; Jean de Gunzburg; Antoine Andremont; France Mentré; Mark H Wilcox
Journal:  J Antimicrob Chemother       Date:  2022-03-31       Impact factor: 5.790

Review 8.  Experimental human hookworm infection: a narrative historical review.

Authors:  Paul R Chapman; Paul Giacomin; Alex Loukas; James S McCarthy
Journal:  PLoS Negl Trop Dis       Date:  2021-12-09

9.  Disease-Alleviating Effects of Peroral Activated Charcoal Treatment in Acute Murine Campylobacteriosis.

Authors:  Stefan Bereswill; Soraya Mousavi; Dennis Weschka; Markus M Heimesaat
Journal:  Microorganisms       Date:  2021-06-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.